Cytolytic T cell lines which bind to complexes of tumor rejection antigens and HLA-B44 molecules
US5744353A · kind A · utility
2Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 1997 |
| Grant date | Apr 28, 1998 |
| Priority date | — |
| Expiry date | Feb 6, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/136
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Tumor rejection antigens presented by HLA-B44 molecules are described. These peptides are useful in diagnostic and therapeutic methodologies. The tumor rejection antigens are derived from MAGE tumor rejection antigen precursors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.